Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma

Trial Profile

Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ARUMM
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 20 Apr 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 07 Dec 2015 Last checked against the European clinical Trials database record
    • 27 Nov 2015 Planned End Date changed from 1 Jun 2020 to 1 Oct 2020, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top